Explore

Rapid Read Rapid Read
AI Analysis of Reddit Posts Reveals Unreported GLP-1 Side Effects

AI Analysis of Reddit Posts Reveals Unreported GLP-1 Side Effects

Researchers at the University of Pennsylvania have utilized AI to analyze over 400,000 Reddit posts, identifying patient-reported symptoms associated with GLP-1 drugs like semaglutide and tirzepatide. These symptoms, which include reproductive issues such as irregular menstrual cycles and temperature-related complaints like chills and hot flashes, may not be fully captured in clinical trials or regulatory documents. The study, published in Nature Health, highlights the potential of social media as a source of information about drug side effects, although the researchers caution that their findings are not causal. The analysis suggests that these symptoms are worth further investigation, as they are clearly on patients' minds.
Rapid Read Rapid Read
AI Analysis of Reddit Posts Reveals Underreported GLP-1 Drug Side Effects

AI Analysis of Reddit Posts Reveals Underreported GLP-1 Drug Side Effects

Researchers at Penn have used AI to analyze over 400,000 Reddit posts, identifying patient-reported symptoms associated with GLP-1 drugs, such as semaglutide and tirzepatide, that may not be fully captured in clinical trials. The study, published in Nature Health, highlights reproductive symptoms like irregular menstrual cycles and temperature-related complaints such as chills and hot flashes. The findings suggest that social media can provide valuable insights into patient experiences and potential side effects that are not always evident in traditional clinical research.
Rapid Read Rapid Read
Genetic Study Reveals Variability in GLP-1 Drug Efficacy and Side Effects

Genetic Study Reveals Variability in GLP-1 Drug Efficacy and Side Effects

A recent study published in Nature has identified genetic variants that influence the efficacy and side effects of GLP-1 receptor agonists, a class of drugs used for weight loss. The research involved a genome-wide association study (GWAS) with 27,885 participants, revealing that a missense variant in the GLP1R gene is associated with enhanced weight-loss efficacy. Each copy of the effect allele predicted an additional 0.76 kg of weight loss. Additionally, genetic variations in GLP1R and GIPR were linked to medication-induced nausea and vomiting, particularly in patients using tirzepatide. The study highlights the role of genetic differences in drug-target genes in modulating therapeutic responses and adverse events.
Rapid Read Rapid Read
BostonGene Showcases AI-Driven Drug Development at AACR Annual Meeting

BostonGene Showcases AI-Driven Drug Development at AACR Annual Meeting

BostonGene, a leader in AI-driven cancer research, is set to present 13 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026. The company will demonstrate its AI foundation model for tumor and immune biology, which integrates genomic, transcriptomic, and spatial insights to accelerate drug discovery and optimize patient stratification. Key presentations include the use of AI-based tools for precision patient stratification, target identification, and prediction of drug-induced tissue dynamics. BostonGene's research highlights the potential of AI to transform the pharmaceutical pipeline by providing biologically grounded insights from early discovery through late-stage clinical trials.
Rapid Read Rapid Read
Genetic Variants Linked to GLP-1 Medication Efficacy and Side Effects Identified

Genetic Variants Linked to GLP-1 Medication Efficacy and Side Effects Identified

A recent genome-wide association study has identified genetic variants that influence the efficacy and side effects of GLP-1 medications, commonly used for weight loss. The study, utilizing data from 23andMe and patient experiences, found a missense variant in the GLP1R gene associated with a modest increase in weight loss. However, non-genetic factors such as sex, drug type, dose, and duration were found to have a more significant impact on variability. Additionally, variations in the GLP1R and GIPR genes were linked to medication-related nausea or vomiting, with the GIPR association specific to users of tirzepatide. These findings were published in Nature.
Rapid Read Rapid Read
Eisai to Present New Alzheimer's Treatment Data at Neurology Meeting

Eisai to Present New Alzheimer's Treatment Data at Neurology Meeting

Eisai Inc. is set to present new findings on lecanemab, an anti-amyloid beta protofibril antibody for Alzheimer's disease treatment, at the American Academy of Neurology's Annual Meeting. The presentations will include mechanistic and biomarker insights, treatment delivery advances, and long-term clinical outcomes. Eisai will also host a symposium on smoldering Alzheimer's disease, focusing on early detection and treatment strategies. The event aims to equip healthcare professionals with evidence-based insights to support earlier detection and stronger patient-care partner conversations.
Rapid Read Rapid Read
23andMe Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

23andMe Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

The 23andMe Research Institute has published a study in Nature identifying genetic predictors for the efficacy and side effects of GLP-1 receptor agonists, which are medications used in weight management. The study involved a genome-wide association study (GWAS) of 27,885 individuals using GLP-1 medications like semaglutide and tirzepatide. The research found that genetic variations in the GLP1R and GIPR genes influence the effectiveness of these medications and the likelihood of side effects such as nausea and vomiting. The study highlights the potential for personalized treatment strategies in obesity management, based on genetic testing.
Rapid Read Rapid Read
Study Identifies Genetic Predictors for GLP1 Receptor Agonist Weight Loss

Study Identifies Genetic Predictors for GLP1 Receptor Agonist Weight Loss

A study published in Nature has identified genetic predictors that influence the efficacy and side effects of GLP1 receptor agonists, medications used for weight loss. Conducted by researchers using data from 23andMe participants, the study analyzed the genetic factors that affect how individuals respond to these medications. The research focused on two main drugs, semaglutide and tirzepatide, and examined the relationship between genetic variations and the drugs' effectiveness in reducing body mass index (BMI) and potential side effects. The study utilized both self-reported data and electronic health records to ensure accuracy and comprehensiveness.
Rapid Read Rapid Read
23andMe Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

23andMe Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

The 23andMe Research Institute has published a study in Nature identifying genetic predictors that influence the efficacy and side effects of GLP-1 receptor agonists, such as semaglutide and tirzepatide, used in weight management. The study involved a genome-wide association study (GWAS) of 27,885 individuals, revealing that variations in the GLP1R and GIPR genes are linked to differences in weight loss efficacy and side effects like nausea and vomiting. These findings suggest that genetic testing could guide more personalized treatment strategies for obesity, addressing the variability in patient responses to these medications.
Rapid Read Rapid Read
Vanderbilt Health Study Reveals Tradeoffs in Weight Loss Treatments Affecting Body Composition

Vanderbilt Health Study Reveals Tradeoffs in Weight Loss Treatments Affecting Body Composition

A study conducted by Vanderbilt Health has highlighted the tradeoffs involved in popular weight loss treatments, including bariatric surgery and GLP-1 receptor agonist drugs. The research, published in JAMA Network Open, indicates that while these treatments lead to significant fat loss, they also result in a reduction of fat-free mass, which includes lean muscle. The study analyzed data from 1,257 patients who underwent bariatric surgery and 1,809 patients treated with semaglutide or tirzepatide. The researchers used bioelectrical impedance analysis to assess changes in body composition over a 24-month period. The findings show that both treatments produce similar patterns of substantial fat mass reduction and modest decreases in fat-free mass, with an overall improvement in body composition.
Rapid Read Rapid Read
Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

A study published in Nature by 23andMe has identified genetic variants that explain the varied responses to obesity drugs like semaglutide and tirzepatide. The research involved nearly 28,000 participants who used 23andMe's DNA-testing service and reported their experiences with weight-loss drugs. The study found that specific genetic variants are associated with greater weight loss and increased risk of side effects such as nausea. These findings provide insights into why some individuals experience significant weight loss while others do not, highlighting the role of genetics in drug efficacy and side effects.
Trendline Trendline
Vanda Pharmaceuticals Initiates Thetis Study to Address Vomiting in GLP-1 Therapy Patients

Vanda Pharmaceuticals Initiates Thetis Study to Address Vomiting in GLP-1 Therapy Patients

Vanda Pharmaceuticals Initiates Thetis Study to Address Vomiting in GLP-1 Therapy Patients